心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JCO：β受体阻滞剂普萘洛尔降低乳腺癌死亡率

2011-06-03 小康 医学论坛网

普萘洛尔乳腺癌
关注

MedSci注：类似这种跨界的药物的研究，文章十分容易发表。如地高辛能增加乳腺癌危险，降血糖药物致癌，降血脂药物诱导心脏疾病，雄激素诱导HA等等。在临床上仔细分析，若能发现不同药物的特殊“副作用”，就是临床的新发现。MedSci已接受并协助大量此类文章的发表。具体可以参考：http://www.medsci.cn/list.asp?classid=110 　　《临床肿瘤学杂志》（J 

MedSci注：类似这种跨界的药物的研究，文章十分容易发表。如地高辛能增加乳腺癌危险，降血糖药物致癌，降血脂药物诱导心脏疾病，雄激素诱导HA等等。在临床上仔细分析，若能发现不同药物的特殊“副作用”，就是临床的新发现。MedSci已接受并协助大量此类文章的发表。具体可以参考：https://www.medsci.cn/list.asp?classid=110

　　《临床肿瘤学杂志》（J Clin Oncol）5月31日在线发表的一项研究提示，抑制β2肾上腺素信号传导通路可降低乳腺癌进展和死亡风险。

　　该研究使用爱尔兰国家癌症登记中心的资料，识别出2001年1月至2006年12月31日诊断的Ⅰ～Ⅳ期浸润性乳腺癌女性患者。研究把诊断乳腺癌1年前使用普萘洛尔（β1/β2阻滞剂，70例）或阿替洛尔（β1阻滞剂，525例）的患者与未使用β阻滞剂的患者（n=4738）进行匹配（1:2）。研究评估了使用阿替洛尔或普萘洛尔与诊断时局部肿瘤浸润（T4期肿瘤）、淋巴结受累或转移（N2/N3/M1期肿瘤）和至乳腺癌特异性死亡时间的相关性。

　　结果显示，与对照者先比，普萘洛尔使用者患T4[比值比（OR）为0.24，95％可信区间（CI）为0.07〜0.85]或N2/N3 /M1（OR为0.20，95％CI为0.04〜0.88）肿瘤的可能性显著更低。乳腺癌特异性累积死亡率显著低于对照者（危险比0.19，95％CI为 0.06～0.60）。使用阿替洛尔者和未使用阿替洛尔者T4或N2/N3/M1期肿瘤的发病率或乳腺癌特异性死亡率无差异。

　　相关链接：Beta Blockers and Breast Cancer Mortality: A Population-Based Study
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1995090, encodeId=ca2619950900e, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 09 03:33:00 CST 2011, time=2011-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890980, encodeId=c47018909801d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sat Jan 21 21:33:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085673, encodeId=8ae120856e3a8, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Nov 13 00:33:00 CST 2011, time=2011-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274905, encodeId=a4fb12e490532, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Jun 05 00:33:00 CST 2011, time=2011-06-05, status=1, ipAttribution=)]
    2011-06-09 tulenzi

    #受体阻滞剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1995090, encodeId=ca2619950900e, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 09 03:33:00 CST 2011, time=2011-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890980, encodeId=c47018909801d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sat Jan 21 21:33:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085673, encodeId=8ae120856e3a8, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Nov 13 00:33:00 CST 2011, time=2011-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274905, encodeId=a4fb12e490532, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Jun 05 00:33:00 CST 2011, time=2011-06-05, status=1, ipAttribution=)]
    2012-01-21 lidong40

    #JCO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1995090, encodeId=ca2619950900e, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 09 03:33:00 CST 2011, time=2011-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890980, encodeId=c47018909801d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sat Jan 21 21:33:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085673, encodeId=8ae120856e3a8, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Nov 13 00:33:00 CST 2011, time=2011-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274905, encodeId=a4fb12e490532, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Jun 05 00:33:00 CST 2011, time=2011-06-05, status=1, ipAttribution=)]
    2011-11-13 zhyy88

    #阻滞剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1995090, encodeId=ca2619950900e, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 09 03:33:00 CST 2011, time=2011-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890980, encodeId=c47018909801d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sat Jan 21 21:33:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085673, encodeId=8ae120856e3a8, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Nov 13 00:33:00 CST 2011, time=2011-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274905, encodeId=a4fb12e490532, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Jun 05 00:33:00 CST 2011, time=2011-06-05, status=1, ipAttribution=)]
    2011-06-05 muzishouyi

    #β受体阻滞剂#

    0